NS-11394
NS-11394 is a drug which acts as a subtype-selective positive allosteric modulator at GABAA receptors, with selectivity for the α3 and α5 subtypes.[1][2] It has been researched as an analgesic for use in chronic or neuropathic pain.[3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H19N3O |
Molar mass | 353.425 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
References
- Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID 18791060. S2CID 36490884.
- Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID 18791063. S2CID 206499795.
- Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID 19729210.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.